While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers; APST Research data includes thousands of people liv ...
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
GlobalData on MSN6d
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 HEALEY ALS basket trial, which is trying to accelerate the search for ...
A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...
Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback